Validation experiment designed to validate causal mechanisms targeting APP, PSEN1 in transgenic mice expressing chimeric mouse-human APP and mutant human presenilin-1. Primary outcome: amyloid load reduction and cognitive improvement
This experiment tested the therapeutic efficacy of engineered TCRAβ-Tregs in a transgenic mouse model of Alzheimer's disease. Mice expressing chimeric mouse-human amyloid precursor protein and mutant human presenilin-1 received adoptive transfer of the engineered TCRAβ-Tregs. The study measured multiple outcomes including behavioral performance, immune responses, and immunohistochemical markers. Key findings included sustained immune suppression, reduced microglial activation, decreased amyloid loads, and improved cognitive functions. 18F-fluorodeoxyglucose labeling was used to track the TCRAβ-Tregs, demonstrating their ability to home to the brain and provide antigen-specific targeting. The results showed that TCRAβ-Tregs could reduce amyloid burden, restore brain homeostasis, and improve learning and memory compared to controls.
Adoptive transfer of TCRAβ-Tregs followed by behavioral testing, immunohistochemistry, and 18F-FDG tracking
Reduced amyloid burden, decreased neuroinflammation, improved cognitive function
Significant reduction in amyloid load and improved performance on cognitive tests
No related hypotheses
No debates yet
No results recorded yet. Use POST /api/experiments/{id}/results to record a result.